reason report
us gx reach new normal fresh look
bottom line past month seen improv
gener industri fundament stabil us gener
price eros trend high-single-digit rang improv
outlook fda abbrevi new drug applic anda approv
rate improv fundament forward ev/ebitda multipl
gener basket expand rang recent
month septemb believ improv
sustain reassess compani valuat reflect
level reassess multipl compani
base rel strength respect busi overal
continu op remain mp
upgrad rate teva mp
could get us construct gener sector
improv us gener price eros nation averag drug
acquisit nadac data suggest price eros actual
consist high-singl low-doubl digit rang last
year step chang price eros trend mid-
singl digit rang would make investor optimist greater first-
time anda approv averag number anda approv
per month last year markedli higher year past
averag number first-tim anda approv per month larg
stay past three year construct
would need see pace first-tim anda approv start
ramp improv visibl longer tail complex gener
opportun share ramp complex gener
copaxon take longer typic small molecul gener
initi year expect longer tail better
visibl ramp curv well long-term outlook
opportun could get us construct opportun
summari valuat chang lower
ev/ebitda slightli primarili due lower outlook
gener busi due manufactur issu
increment posit specialti side due growth
biosimilar amneal multipl slightli higher
continu see gener pipelin best-in-class
specialti side rytari continu put strong growth endo
overal multipl unchang increas multipl
gener reflect improv perform sector off-set
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
lower specialti multipl reflect signific hit outer-year
sale estim gener vasostrict adrenalin teva rais
multipl reflect better fundament across
aspect busi revalu gener segment base
stronger peer group multipl specialti outlook markedli
improv due delay impact copaxon proair gener
along strong austedo perform time ajovi approv
lower multipl vs previous incorpor
increas gener peer group multipl assign rel
discount gener biz given limit visibl proair
approv timelin addit pipelin opportun behind
well uncertainti around multipl obtain sale
separ segment also lower consum cx /otc
multipl line teva look better visibl
long-term growth beyond current low-singl digit level
initi coverag gener sector januari view gener
fundament like remain pressur near term forward month
sign appear gotten wors believ still prematur suggest
outlook get significantli better key factor impact industri
reach new normal gener price declin appear stabil y/i
declin remain high-singl low-doubl digit rang past year
base industri check expect pressur price custom get wors
anda approv continu record high rate compani alreadi taken hit low-
profit commodit product portfolio de-prioritized/ discontinu
product thu headwind may start less less impact go forward
final fda start approv complex product potenti
significantli posit impact growth speed approv come
increment best current said slow uptak certain complex gener
copaxon suggest cautiou outlook type opportun warrant
us gx price continu stabl
price stabil seen throughout view nadac price trend serv
proxi us gx price well correl gener multipl seen
stabil us gx price appear gener multipl expand
one might note peak multipl seen januari short live
believ time around level like sustain
seen better stabil price eros rate price equal across buy consortium
manufactur either discontinu simpli choos launch commodit product
also improv industri trend fda approv rate fda
commit approv complex product
commentari manag team follow gx/biosimilar bu tour larg mirror
weve heard throughout year consolid big consortium
meant cessat price equal seen top compani endo
made necessari chang us gx portfolio put emphasi
profit also shift focu sustain higher valu opportun insid
gener
figur nadac y/i price chang forward ev/ebitda multipl gx basket
fda continu record pace approv first-tim approv still catch
quantiti anda approv remain high qualiti complex approv slowli start
come ratio first time overal gx approv remain low partial
due record high volum new gx product get approv fda number
first time gx approv larg constant last three year certainli
exampl one point product final cross fda goal line follow extend
wait welchol amneal epipen teva product advair restasi
would also fit categori assum final see first gener approv
figur monthli anda approv mix first time approv
gener approv
figur first time gx approv month
outlook growth new complex gener opportun improv still
base industri check believ fda remain commit approv
complex gener opportun also start see increas approv
rate improv gradual rather bolu approv come togeth
complex gener take longer gain market share brand compani
defend aggress good exampl gx copaxon mani complex
gener could remain limit competit market much longer typic small
molecul result may see start see revenu stream product
sustain longer durat could drive multipl expans sector
howev still earli stage emerg trend would need see
uptick first-tim new anda approv get better visibl competit
dynam market matur order get posit sector
refresh valuat across gener coverag
month septemb forward ev/ebitda multipl across gener comp
univers highest sinc januari level
otherwis seen sinc earli highlight earlier note believ
price continu remain stabl
analyz correl nadac price eros data forward
ev/ebitda multipl figur result highlight figur base
linear regress equat gener suggest price eros remain
rang would expect multipl
figur correl monthli nadac y/i chang x-axi forward
improv stabil price trend recent month seen expans
sector multipl reach level reflect price eros rang
along improv outlook new anda approv
figur evolut impli gener multipl vs actual sinc march
time improv industri trend believ multipl rang
sustain updat valuat multipl reflect howev believ
earli tell see signific improv fundament
figur ev/ebitda across gener coverag
follow assess broader valuat trend gener take closer look
impact valuat methodolog across gener coverag recal use
sum-of-the-part sotp analysi reflect hybrid busi segment gener
specialti consumer/otc busi compani valu
segment rel respect peer group multipl assign multipl
segment compani base rel strength growth outlook final
report complet roll net debt contribut valuat
reflect state busi vs previous
figur highlight chang assign multipl across compani gener
coverag well chang price target
figur chang valuat across gener coverag
close ev/ebitda multiplepric targetupside/downsidelp stockrat figur highlight project top-lin growth profil compani segment
ev/ebitda multipl assign segment premium/discount
figur chang valuat across gener coverag
follow section summar rational assign correspond
ev/ebitda multipl respect compani
specialti assign multipl amneal brand busi line comp rytari
continu grow nice expect face competit meanwhil albenza
expect face gener competit year zomig like face competit
overal model busi grow compound-annual-growth-rate note manag
ev/ebitdamultiplepremiumsal compound-annual-growth-rate base near-term intent augment specialti segment busi develop
time incorpor credit top line multipl
gener assign multipl amneal gener busi repres premium
comp mostli consist prior multipl segment reflect
compani strong pipelin manag team model gener segment grow
compound-annual-growth-rate compound-annual-growth-rate stand among peer group
manag limit competit asset gx vagifem voltaren gel aggrenox
epinephrin autoinjector levothyroxin meaning contributor start term
new product approv ytd amneal receiv fda approv believ
manag continu drive approv pipelin next year
specialti assign multipl endo brand busi repres
discount comp estim specialty/establish brand segment grow
year compound-annual-growth-rate driven compound-annual-growth-rate xiaflex howev see steril inject
segment declin compound-annual-growth-rate even inclus contribut somerset
nevakar due gener competit vasostrict adrenalin outer year overal
endo specialti segment one gener coverag assum declin
next five year believ warrant discount rel peer group
gener multipl gener busi repres discount comp
although indic previous believ across coverag multipl
gener high consid us price fda approv trend believ endo gener
segment larg stabil go forward gener busi y/i growth
endo key pipelin asset ciprodex amitiza dexil reach market
specialti multipl assign line comp note brand
segment cagr respect highest across
gener compani coverag howev discount multipl base investor sentiment
around compani corpor govern growth essenti driven
entir biosimilar launch point still earli day see mylan
execut opportun realiz commerci potenti
gener multipl discount peer group incorpor discount
peer group histor trade also reflect estim
cagr respect similar endo across three
geograph segment model essenti consist growth gener segment low-
cx/otc model mylan cx/otc busi grow low-singl digit rang believ
multipl line comp appropri
specialti assign multipl teva brand busi repres premium
comp model compound-annual-growth-rate equal amneal assign premium
teva due greater depth product portfolio brand asset austedo
ajovi meaning growth driver next year teva done good job
maintain copaxon revenu expect continu realiz benefit
delay gener proair approv
gener multipl assign repres discount comp surfac
model compound-annual-growth-rate compani gener
coverag due expect y/i declin us howev
teva still far largest anda pipelin among peer mix
opportun smaller potenti higher p-iv volum product ampyra gilenya
larger potenti limit competit asset nuvar forteo
cx/otc single-digit growth teva cx/otc busi appear sustain form
basi multipl line comp
gener multipl discount comp see gx androgel
proair potenti two key opportun busi time
gener proair approv remain unclear beyond two product limit
visibl addit specif growth driver also believ light recent deal
risk multipl obtain segment sale separ
ev/ebitda multipl would impli revenu multipl sale
notabl higher recent deal execut aurobindo sandoz transact
cx/otc assign multipl consum busi line comp
continu model segment grow low-singl digit look greater detail
manag way augment growth becom construct
reassess valuat use stock select criteria
continu best valu play improv outlook teva base continu
win continu believ under-valued strong balanc sheet posit
key product opportun gx advair get closer closer approv
fulphila econom highli favor adopt amneal second pick
among gener name manag continu larger uniqu opportun
portfolio levothyroxin epinephrin autoinjector gx vagifem rate new anda
approv amneal pick engin continu churn
opportun continu recommend endo stabl gener
busi growth outer year although see uncertainti potenti cch
cellulit well uncertain sale potenti nevakar/somerset face certain
gener competit vasostrict adrenalin combin total compani sale
teva move market perform compani manag postpon
meaning gener impact copaxon proair continu grow austedo nice get
time approv fremanezumab final remain market perform
cautiou valu compani rx busi fetch manag well-posit
balanc sheet drive growth although continu see uncertainti exactli
compani drive chc segment low-singl digit level detail
valuat use stock select criteria figur
new amneal chang top-lin growth profil oper margin
improv low-mid-teen driven stand-alon impax
cost save addit higher margin amneal busi impax brand/gener hybrid
biz cost synergi amneal combin see strong profit cash
flow drive improv leverag estim
provid manag flexibl explor addit busi develop
use weight averag ev/ebitda multipl deriv pt
ebitda visibl drive amneal higher
limit visibl composit amneal portfolio delay amneal pipelin product
develop cost save delay lower expect
ep expect declin y/i believ ep grow
compound-annual-growth-rate manag continu execut margin expans
initi focu key product opportun addit litig liabil unlik
view larg expect see increment progress front
believ combin factor drive multipl expans stock
price target base ebitda ev/ebitda
multipl drive upsid stock current level
risk includ faster-than-expect eros vasostrict adrenalin litig remain
drain cash delay time new gx launch lower-than-expect growth steril
inject cellulit opportun may larg anticip
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver
could expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair may get approv commerci uptak biosimilar may take longer
anticip growth ou market may slower expect market penetr
gener copaxon may improv biosimilar neulasta may slower estim
rate market perform believ consum healthcar america chca like
continu grow low-singl digit consum healthcar chci also
grow low-singl digit growth potenti manag initi take time
play howev unclear decis separ rx busi immedi
unlock valu enhanc growth consum healthcar segment
current still limit visibl medium-/long-term growth trajectori busi
use ebitda appli weight averag ev/ebitda multipl
arriv pt
limit rx-to-otc switch opportun and/or delay new rx over-the-counter product launch
could result share trade lower expect initi drive busi may
success anticip lead share perform better expect
attribut neutral outlook due five main factor brand copaxon continu
hold volum share austedo track sale year gx proair
delay yet potenti earliest ajovi approv time
septemb cost trend level even manag initi guidanc
still see risk consensu number believ matter
time meaning gener competit hit copaxon proair still struggl see
growth us gener believ manag done good job stabil busi
build block place busi grow start rate teva market
perform price target
price target base ebitda ev/ebitda multipl
continu delay new gener opportun slower-than-anticip ramp ajovi could
result teva trade lower price target addit delay gener competit
copaxon proair along faster growth austedo could result teva trade
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
herceptin approv launch
neulasta approv launch
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
chang account receiv
chang inventori
chang account payabl
chang incom tax
chang current liabil
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
number except per share data
slight declin time
net debt ebitda ratio
note number repres full-year amneal
commit long-term
number except per share data
number except per share data
budesonid pulmicort respul -- teva
number except per share data
estrac approv expect launch
number except per share data
number except per share data
aggrenox approv launch
tamiflu approv launch
nasonex approv launch
zetia approv launch
minastrin fe approv launch
copaxon gener alreadi market pend approv
gleevec gener alreadi market pend approv
viagra launch teva day exclus tent approv
seroquel xr gener alreadi market pend approv
lialda launch jan zydu day exclus expir
copaxon gener alreadi market pend approv
canasa assum ftf day exclus pend approv
exelon patch gener alreadi market pend approv
faslodex litig progress assum settlement ftf sandoz pend approv
number except per share data
norvir assum patent expir jan pend approv
saphri filer lost patent pend approv
truvada assum emtricitabin patent key pend approv
amitiza assum settlement month ftf pend approv
sensipar case progress pend approv
vimpat lost patent expir pend approv
toviaz filer lost patent expir tent approv
velcad filer lost patent expir pend approv
alimta filer lost patent pend approv
vyvans lost feb patent tent approv
xyrem assum launch day hikma pend approv
onglyza franchis lost jul patent pend approv
number except per share data
sale
note number repres full-year amneal
number except per share data
prepaid expens current
accru profit share royalti
liabil held sale
current portion ltd
number except per share data
adjust reconcil ni net cash oper
tax expens stock option rsa
accru profit share royalti expens net payment
reserv ture receiv
sale asset
loss extinguish debt
net chang fair valu deriv
recognit defer revenu
chang fair valu conting consider
decreas increas work capit
payment busi acquisit
purchas properti plant equip capital-expenditure
payment licens agreement
invest cash surrend valu insur
proce repay tolmar loan
proce sale intang asset
maturities/purchas short-term invest
net invest
payment defer financ fee
purchas bond hedg deriv asset
proce sale warrant
tax benefit stock option rsa
proce exercis stock option espp
net financ
effect exchang rate chang cash/ cash equival
net chang equival
number except per share data
net debt ebitda ratio
number except per share data
declin low-teen
number except per share data
vasostrict assum gener
adrenalin inject assum gener
steril inject previous new launch alt dosag
total steril inject previous new launch alt dosag
growth high teen
number except per share data
us gener previous new launch altern dosag
us gener previous new launch alt dosag
number except per share data
ftf/ftm key pipelin
effient assum entri expiri w/ ped oct pend approv
axiron assum get approv
epiduo assum get approv
concerta assum get approv mid
pylera sole ftf assum month dec patent expiri pend approv
ampyra assum launch jul patent expir pend approv
namenda xr appeal progress assum favor outcom pend approv
tikosyn assum oct patent expiri pend approv
uceri assum patent invalid hold oct launch pend approv
afinitor assum launch time-frame tent approv
zortress assum launch time-frame pend approv
ciprodex date certain entri pend approv
samsca assum entri patent expiri pend approv
zomig assum entri may patent expiri pend approv
onglyza assum entri comp patent expir pend approv
xyrem assum launch day hikma pend approv
dexil assum settlement patent expir approv
number except per share data
ftf/ftm key pipelin sub-tot
number except per share data
total litha somar
number except per share data
restrict cash cash equival
prepaid expens current asset
asset held sale
account payabl accru expens
current portion legal settlement
current portion ltd
liabilit held sale
number except per share data
adjust reconcil ni net cash oper
amort debt issuanc cost discount
provis bad debt
chang fair valu conting consider
loss extinguish debt
sale busi asset
decreas increas work capit
purchas properti plant equip capital-expenditure
acquisit businesses/asset net cash acquir
patent acquisit cost licens fee
proceed sale busi
increas restrict cash cash equival
net invest
borrow repay revolv credit/oth net
payment conting consider
tax benefit share award
payment tax withhold restrict share
exercis option
issuanc ordinari share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
number except per share data
net debt ebitda ratio
number except per share data
long term growth
gsk product yokeb
gx bodi oil dermat
gx estrac estradiol vagin cream expect launch
gx finacea foam azela acid progress month stay expir juli
gx soolantra cream ivermectin rosacea ftf case progress
gx prolensa bromfenac ophthalm solut confidenti settlement assum compound patent tent approv
number except per share data
ebiat
number except per share data
tysabri royalti stream fair valu
payrol relat tax
number except per share data
adjust reconcil ni net cash oper
tysabri toyalti stream chang fair valu
loss extinguish debt
impair equiti invest net
decreas increas work capit
proce royalti right
acquisit businesses/asset net cash acquir
proceed sale busi
settlement acquisition-rel foreign currenc deriv
purchas properti plant equip capital-expenditure
net invest
borrow repay revolv credit/oth net
premium earli debt retir
issuanc ordinari share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
number except per share data
share assoc co
net debt ebitda ratio
number except per share data
number except per share data
number except per share data
disclos ftf notabl pipelin
viagra sildenafil dec settlement exclus
viread tenofovir dec settlemnet exclus
reyataz atazanavir dec settlement exclus
byetta exenatid inj oct settlement exclus
effient prasugrel launch patent expiri oct
butran launch sept patent expir
nuvar appeal state patent valid pend approv
renvela assum approv pend approv
acanya jul settlement exclus approv
pazeo settlement may pend approv
exjad assum month patent expiri approv
moviprep settlement sept pend approv
solodyn feb feb launch specif strength approv
uceri assum patent invalid hold oct launch pend approv
letairi undisclos settlement assum month last patent pend approv
levitra assum month patent tent approv
restasi patent invalid await appeal assum launch pend approv
number except per share data
noxafil drt assum compound patent expir jul hold pend approv
zubsolv sept patent upheld court pend approv
latuda lost jan patent tent approv
rozerem undisclos settlement assum jul compound expiri approv
zyclara settlement jul pend approv
vigamox assum month patent expiri approv
abraxan ode exclus pend approv
absorica settlement dec pend approv
silenor settlement jan exclus approv
tarceva undisclos settlement assum may expiri polymorph patent pend approv
diclegi assum month patent expiri approv
atripla/truvada undisclos settlemnet assum last patent emtricitabin expir gate approv
rayo settlement approv
xopenex hfa assum month patent expiri pend approv
onglyza franchis patent upheld court pend approv
disclos ftf notabl pipelin sub-tot
number except per share data
number except per share data
number except per share data
number except per share data
number except per share data
number except per share data
asset held sale
sale reserv allow
liabil held sale
tax long-term liabil
senior note loan
number except per share data
adjust reconcil ni net cash oper
impair long-liv asset
net gain loss sale long-liv assets/invest
translat adjust due venezuela devalu
research develop process
impair equiti invest net
decreas increas work capit
sale purchas busi net cash acquir
proce sale long-liv asset invest
purchas properti plant equip capital-expenditure
purchas invest asset
net invest
dividend paid ordinari share
proce issuance/ purchas ordinari share net
proce issuanc prefer share net
dividend paid prefer share
dividend paid non-control interest
proce exercis option employe
purchas treasuri shares/ ordinari share
net financ
translat adjust cash cash equival
net chang equival
